A pioneering clinical study has revealed that providing pluripotent cells to unborn babies affected by spina bifida as part of a surgical repair can be a "major milestone" in treating birth defects.
Trial Details and Safety
The US-based trial focused on six developing infants with the 'open' form of spina bifida. Medical teams placed mother's placental stem cells on the exposed area of the infant's spine while the defect was being closed.
Importantly, the cell therapy was found to be safe. Doctors verified that the cells did not cause tumors, disrupt the healing process, or prevent the reversal of associated brain abnormalities.
Promising Outcomes
Imaging conducted after delivery confirmed a full resolution of hindbrain herniation in each of the babies. This neurological improvement is strongly associated with improved motor skills and quality of life.
"If it makes a greater number of infants able to walk who previously could not, it may emerge as the new treatment paradigm," noted the study director. "The outcomes appear super exciting and open the door to lots of potential new treatments."
Broader Impact and Encouragement
Experts not involved in the trial indicated that additional validation of these noted improvements could announce a "different age" in prenatal intervention. The prospect of enhancing nerve function impairment seen in utero is considered a transformative goal.
Particularly welcome would be improvements in continence and digestive health, which are frequent complications for those diagnosed with this disorder.
Future Directions
Despite this being a first-in-human effort was small in scale, its established security and encouraging indicators offer a robust platform for expanded clinical research. The integration of stem cell therapy with current in-utero repair procedures presents significant potential for improving the prognosis for babies yet to be born with spina bifida.